Former New York City Mayor Rudy Giuliani unleashed a long-winded rant against a New York judge on Tuesday, telling reporters that the jurist, appointed by then-President Donald Trump , is an "activist Democrat." "Have you figured out what side he's on?" Giuliani told reporters Tuesday, referring to U.S. District Judge Lewis Liman. "Are you too dumb to see what side he's on?" "I've been a lawyer for 55 years," Giuliani added, according to Politico. "I can figure out what side he's on." Trump nominated Liman to serve on the U.S. District Court for the Southern District of New York in May 2018. He was confirmed by the Senate in December 2019 by a vote of 64-29. Giuliani, also a former Trump attorney, added that Liman "doesn't give a damn about the truth. He just gives a damn about being popular." His rant against Liman arrived after the two men were embroiled in a heated back and forth at a pretrial hearing in New York related to a $148 million defamation lawsuit that two former Georgia election workers filed against Giuliani. Liman asked Giuliani in court why he hadn't handed over the title to his Mercedes-Benz convertible to the two election workers, Ruby Freeman and Shaye Moss, as ordered by the court. Giuliani said he had requested a duplicate title for the car but that it hadn't been issued yet. "The implication I have not been diligent about it is totally incorrect," he said. "The implication you make is against me and every implication against me is wrong." "I don't have a car," Giuliani said, according to Politico. "I don't have a credit card. They have put a stop order on, for example, my Social Security account," he added, referring to Freeman and Moss. But Liman cut Giuliani off, telling him, "I permitted Mr. Giuliani to speak. Next time, I will not permit him to speak and the court will have to take action." Giuliani has been consumed by legal troubles since the 2020 election. In July, he was disbarred in New York over efforts to overthrow the election results that year and deliver Trump the White House. The former mayor made "demonstrably false and misleading statements to courts, lawmakers, and the public at large in his capacity as lawyer for former President Donald J. Trump and the Trump campaign in connection with Trump's failed effort at reelection in 2020," the New York appeals court wrote in its ruling. Two months later, Giuliani was disbarred in Washington, D.C. Giuliani also faces criminal cases in Georgia and Arizona over election subversion efforts, and he was also hit with defamation lawsuits from voting technology companies Dominion Voting Systems and Smartmatic. Newsweek reached out to a Giuliani spokesperson for comment on Tuesday.TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business. During the fiscal year, the company pivoted the in-house development of its anti-TLR4 drug candidate, EB05 (paridiprubart), to a U.S. government-funded study investigating novel threat-agnostic host-directed therapeutics in patients with Acute Respiratory Distress Syndrome (ARDS). Given this opportunity, Edesa is also amending a development and drug manufacturing project for the same asset that is supported by the Government of Canada. The company said that the goal is to maximize synergies between the two government-funded projects. For its anti-CXCL10 program, Edesa intends to manufacture EB06 and submit related data to the U.S. Food and Drug Administration as part of an investigational new drug (IND) application. The manufacturing of clinical-grade drug batches and initiation of the patient enrollment is subject to funding. Edesa anticipates topline results for this Phase 2 study could be available within as few as 12 to 18 months following regulatory clearance in the U.S. The study is currently approved in Canada. “This year, Edesa maintained its momentum despite the headwinds in the drug development sector, and we once again validated our TLR4 technology with a third competitive government award,” said Par Nijhawan, MD, Chief Executive Officer of Edesa Biotech. “I have maintained my strategic support financially and I believe that our team can continue to advance and expand our development pipeline and partnerships.” Edesa's Chief Financial Officer Stephen Lemieux reported that financial results for the fiscal year benefited from prudent use of working capital and effective financial management, including a more than 20% decrease in operating expenses. “Following the end of the fiscal year, we strengthened our balance sheet, and with two governments now funding the advancement of our anti-TLR4 technology, we have improved our position for future financing, potential strategic arrangements as well as other opportunities to advance our pipeline.” Financial Results for the Fiscal Year Ended September 30, 2024 Total operating expenses decreased by $2.2 million to $7.0 million for the year ended September 30, 2024 compared to $9.2 million for the prior year: Research and development expenses decreased by $1.9 million to $2.9 million for the year ended September 30, 2024 compared to $4.8 million for the prior year primarily due to decreased external research expenses related to the company’s completed dermatitis study and a reduction in labor costs and noncash share-based compensation, which were partially offset by an increase in expenses related to manufacturing of paridiprubart. General and administrative expenses decreased by $0.3 million to $4.1 million for year ended September 30, 2024 compared to $4.4 million for the prior year primarily due to a decrease in noncash share-based compensation, which was partially offset by an increase salaries and related costs. Total other income was unchanged at $0.8 million for the years ended September 30, 2024 and September 30, 2023 as a $0.1 million increase in reimbursement funding from the Canadian government's Strategic Innovation Fund was offset by a $0.1 million decrease in interest income. For the year ended September 30, 2024, Edesa reported a net loss of $6.2 million, or $1.93 per common share, compared to a net loss of $8.4 million, or $2.93 per common share, for the year ended September 30, 2023. Working Capital At September 30, 2024, Edesa had cash and cash equivalents of $1.0 million and negative working capital of $0.2 million. Subsequent to the fiscal year end, the company received $1.5 million in gross proceeds under a securities purchase agreement with an entity affiliated with Edesa’s Chief Executive Officer and Founder, and $0.6 million in net proceeds, after deducting sales agent commissions, from common shares sold under an at-the-market offering program. Calendar Edesa management plans to participate in one-on-one meetings during JP Morgan week, which begins on January 13, 2025, in San Francisco, California. Attendees interested in meeting with management can request meetings through the conference organizers or by contacting Edesa directly at investors@edesabiotech.com . About Edesa Biotech, Inc. Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company’s most advanced Respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a U.S. government-funded platform study as a treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. The EB05 program has been the recipient of two funding awards from the Government of Canada to support the further development of this asset. In addition to EB05, Edesa is preparing an investigational new drug application (IND) in the United States for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis. Sign up for news alerts . Connect with us on X and LinkedIn . Edesa Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions, including statements related to: Edesa’s ability to pivot the in-house development of its anti-TLR4 drug candidate; the company’s plans to amend its contribution agreement with the Government of Canada; the company’s goal to maximize synergies between two government-funded projects; Edesa plans to manufacture EB06 and submit related data to the FDA as part of an IND application; the company’s plans to manufacture clinical-grade drug and initiate patient enrollment; the company’s plans to finance clinical and manufacturing activities; the company’s estimate that topline results for its Phase 2 vitiligo study could be available within as few as 12 to 18 months following regulatory clearance; the company’s belief that in 2024 it maintained its momentum despite the headwinds in the drug development sector and once again validated its TLR4 technology with a third competitive government award; the company’s belief that its team can continue to advance and expand its development pipeline and partnerships; the company’s belief that its fiscal year financial results benefited from prudent use of working capital and effective financial management; the company’s belief that with two governments funding the advancement of its anti-TLR4 technology, it has improved its position for future financing, potential strategic arrangements and alternatives as well as other opportunities to advance its pipeline; and the company's timing and plans regarding its clinical studies in general. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum." Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC "Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem. Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" 1914 translation by H. Rackham "But I must explain to you how all this mistaken idea of denouncing pleasure and praising pain was born and I will give you a complete account of the system, and expound the actual teachings of the great explorer of the truth, the master-builder of human happiness. No one rejects, dislikes, or avoids pleasure itself, because it is pleasure, but because those who do not know how to pursue pleasure rationally encounter consequences that are extremely painful. Nor again is there anyone who loves or pursues or desires to obtain pain of itself, because it is pain, but because occasionally circumstances occur in which toil and pain can procure him some great pleasure. To take a trivial example, which of us ever undertakes laborious physical exercise, except to obtain some advantage from it? But who has any right to find fault with a man who chooses to enjoy a pleasure that has no annoying consequences, or one who avoids a pain that produces no resultant pleasure?" To keep reading, please log in to your account, create a free account, or simply fill out the form below.By WYATTE GRANTHAM-PHILIPS NEW YORK (AP) — A ransomware attack that hit a major software provider last week caused disruptions for a handful of companies over recent days, from Starbucks to U.K. grocery giant Morrisons. Blue Yonder, which provides supply chain technology to a range of brands worldwide, said that it experienced disruptions to services it manages for customers on Thursday, which the third-party software supplier determined to be “the result of a ransomware incident.” Some systems went offline, impacting clients using Blue Yonder’s software. A spokesperson for Starbucks, for example, said that the chain’s ability to manage barista schedules and track hours was disrupted — meaning store leaders across North America are currently being instructed to use manual workarounds. Starbucks maintained that the outage is not impacting how customers are served and that ensuring workers get paid for all hours worked is a top priority. While the company continues to work towards full recovery, the spokesperson added that Starbucks was able to process payroll again as of Tuesday morning. Two of the U.K.’s biggest grocers, Morrisons and Sainsbury’s, were also affected — with both telling CNN over the weekend that they had turned to contingency plans to keep operations flowing. A spokesperson for Morrisons confirmed to The Associated Press that the outage “impacted our warehouse management systems for fresh and produce” and that it was continuing to operate on back up systems Tuesday. Sainsbury’s, meanwhile, said Tuesday that its service was restored. Related Articles National News | Ex-FBI informant accused of lying about the Bidens is indicted on federal tax charges National News | Bird flu virus was found in raw milk. What to know about the risks National News | Walmart’s DEI rollback signals profound shift in the wake of Trump election victory National News | Man found guilty of holding down teen while he was raped at a youth center in 1998 National News | So you’re gathering with relatives whose politics are different. Here are some tips for the holidays Blue Yonder declined to disclose how many of its customers were impacted by the hack. In a statement sent to the AP, a spokesperson maintained that it had notified “relevant customers” and would continue to communicate as needed. The spokesperson also maintained that recovery efforts were still underway — noting that Blue Yonder “has been working diligently together with external cybersecurity firms to make progress,” including the implementation of several defensive and forensic protocols. Blue Yonder’s website touts an extensive global roster of customers — including Gap, Ford and Walgreens. Walgreens and Gap were not impacted following the ransomware attack, spokespeople for the companies said. Ford shared that it was investigating whether the incident affected its operations earlier this week, but had no further updates when reached Tuesday. Blue Yonder, based in Arizona, is a subsidiary of Japan’s Panasonic Corp. Panasonic acquired the supply chain software firm in September 2021.Foley is here to help you through all aspects of rethinking your long-term business strategies, investments, partnerships, and technology. Contact the authors, your Foley relationship partner, or our Automotive Team to discuss and learn more. Key Developments Foley & Lardner announced the 2024 installment of its Auto Trends series—A Year in Review: Updates, Trends and the Road Ahead . This series delves deep into the transformative forces shaping the automotive world by providing weekly insights and analysis tailored to help business leaders navigate a shifting market landscape. The first two articles in the series address the regulatory themes and outlook for the National Highway Traffic Safety Administration , and potential scenarios for a realignment of the EV and EV infrastructure market . manufacturing under President-elect Donald Trump’s administration in the Pitchbook article, “ Manufacturers prep for a new tariff regime .” President-elect Donald Trump in a November 25 social media post stated he would impose additional 10% tariffs on goods from China , and 25% tariffs on all products from Mexico and Canada for the nations’ alleged facilitation of illegal immigration and fentanyl abuse in the U.S. In response, officials from Canada and Mexico indicated retaliatory tariffs would be pursued. [ News coverage of this development is rapidly evolving .] The cost of tariffs on imported vehicles or components would eventually be passed along to consumers in the form of higher vehicle prices , according to commentary from S&P Global Mobility. The New York Times reported the effects of U.S. tariffs on Mexico’s auto industry “would be profound , affecting the price in the United States of popular models like Ford Maverick pickups, Chevrolet Equinox sport-utility vehicles and several variations of Ram trucks.” A number of provincial leaders in Canada recently called for a bilateral trade agreement between the U.S. and Canada that would exclude Mexico. In response, Prime Minister Justin Trudeau indicated that including Mexico in the U.S.-Mexico-Canada trade agreement is his “first choice,” but he is “leaving all doors open.” Political leaders in the U.S. and Canada have expressed concerns over the potential for Chinese goods to avoid tariffs by entering the North American market through Mexico , a claim Mexican President Claudia Sheinbaum has disputed , as well as the possibility that Chinese companies such as BYD could soon establish manufacturing operations in Mexico. As part of a goal to dismantle Biden administration policies that have been described as equivalent to an “EV mandate,” the incoming Trump administration signaled an intent to weaken the National Highway Traffic Safety Administration’s Corporate Average Fuel Economy (CAFE) standards and the Environmental Protection Agency’s tailpipe emissions requirements . The first Trump administration overturned similar Obama-era vehicle fuel economy and emissions regulations. The Alliance for Automotive Innovation urged President-elect Donald Trump to maintain the $7,500 consumer tax credit for qualifying EV purchases , and to establish policies to accelerate the deployment of autonomous vehicles . The industry association also suggested revisions to vehicle emissions and fuel-economy regulations , as well as the need to rethink a requirement to equip nearly all new light vehicles with advanced automatic emergency braking systems by 2029. Wood Mackenzie analysis indicates a potential revision or repeal of federal EV subsidies , as well as fuel economy and vehicle emissions rules ,could lower projected U.S. EV sales by nine percentage points to 23% of new light vehicles by 2030 . The analysis also predicts hybrid vehicles could achieve a U.S. market share of 18% by 2030 . Consultancy AlixPartners predicted that up to $129 billion of EV investments in North America through 2027 are “at risk” due to anticipated Trump administration policiesthat are expected to be unfavorable to EVs , as well as the expectation automakers will delay or cancel BEV models and further reduce electrification expenditures. Members of President-elect Donald Trump’s transition team indicated that establishing a federal framework for autonomous vehicles could be among the Transportation Department’s top priorities, according to unnamed sources in Bloomberg . Foley & Lardner provided highlights from the MEMA Original Equipment Suppliers Annual Conference held on November 12 and 13 in Novi, Michigan. During the conference, at least one automotive analyst remarked on the risk of excessive inventory levels and underutilized manufacturing capacity. OEMs/Suppliers Automotive News summarized remarks by Ford and GM regarding the automakers’ scenario planning ahead of the incoming Trump administration . Stellantis is exploring potential revisions to its manufacturing and sourcing strategies in the event Trump administration policies affect supply chains, and the automaker indicated it could revisit a plan to expand production and sourcing from lower-cost countries if new tariffs are imposed. GM will lay off approximately 1,000 workers worldwide , and a significant portion of the reductions will affect employees at the Global Technical Center in Warren, Michigan. This follows layoffs of over 1,000 software and services employees in August 2024 . A report in The Detroit News estimates Stellantis has laid off over 3,750 hourly workers in the U.S. in recent months. Ford will eliminate 4,000 employees in Europe, equivalent to 14% of the region’s workforce, by the end of 2027 because of economic challenges, increased competition and weaker-than-anticipated EV sales. The majority of the reductions will occur in Germany . Volkswagen’s union workersin Germany could begin mass walkouts in December if an agreement is not reached during negotiations over the automaker’s planned cost reductions. VW’s labor costs in Germany are reported to be higher than competitors that include BMW and Mercedes. Ford will reallocate 400 hourly workers following reduced Bronco production at the Michigan Assembly Plant in Wayne, MI. Electric Vehicles and Low EmissionS Technology During a panel at the MEMA Original Equipment Suppliers Annual Conference , purchasing executives at three major automakers assured suppliers of transparency for evolving product plans and EV programs. Volkswagen increased its potential investment in Rivian by $800 million to $5.8 billion, as part of a joint venture to advance both in-vehicle software capabilities and EV development . VW previously invested $1 billion in the EV maker as part of a collaboration announced earlier this year. S&P Global Market Intelligence estimates global private equity and venture capital deal value in EVs and EV components reached $3.32 billion in the first three quarters of 2024, compared to $4.03 billion raised by non-EV companies in the same period. Global private equity deal value in EV charging infrastructure from January through October 18, 2024, reached $1.04 billion, according to data from S&P Global Market Intelligence. This compares to a deal value of $1.11 billion in full-year 2023. Swedish battery maker Northvolt AB filed for Chapter 11 bankruptcy protection in the U.S. Separately, Northvolt recently sold certain production assets to Lyten , a California-based lithium-sulfur battery maker. Rivian received approval for a conditional loan of up to $6.6 billion from the Department of Energy to expand EV production. Separately, LG Energy Solution was awarded a five-year battery supply agreement for Rivian’s R2 crossover model. Ford will no longer participate in a joint venture manufacturing plant in Quebec that will produce battery materials for EVs. Construction on the cathode active materials plant is already underway and it is expected to continue, according to a report in La Presse . Workers at the Ford – SK On battery joint venture plant in Kentucky signed union authorization cards to begin a campaign to join the UAW. Stellantis delayed the launch of the 2025 Ram 1500 REV electric pickup truck and its range-extended version to the first half of 2025 from the end of this year. The automaker is also working toward two additional EV launches, the Dodge Charger Daytona muscle car and the Jeep Wagoneer S SUV . EVgo hopes to close a U.S. Energy Department $ 1.05 billion conditional loan guarantee for up to 7,500 fast-charging stalls ahead of the incoming Trump administration. Chinese EV makers delivered 9.75 million EVs to mainland buyers in the first ten months of 2024, reflecting an increase of 34% compared to the same period last year. BYD could surpass Ford in worldwide annual shipments this year, and the milestone would establish the Chinese EV maker as a top 10 global automaker measured by unit volumes. California Governor Gavin Newsom plans to offer EV rebates to consumers in the state if the federal tax credit of up to $7,500 for qualifying EV purchases is eliminated. Stellantis plans to add a hybrid model to the Jeep lineup sometime next year, according to an announcement at the Los Angeles Auto Show . Kia intends to produce the 2025 EV6 compact electric crossover at its plant in Georgia , and the vehicle will begin sales in the first half of next year. Hyundai’s 2026 Ioniq 9 electric SUV will have three-row seating and an estimated 300 miles of range. Hyundai and Kia will recall over 200,000 EVs in North America over a defect that may cause the loss of drive power. Automated, Autonomous or Connected Vehicles Technologies GM autonomous driving unit Cruise agreed to pay a $500,000 criminal fine to end claims that it made false statements to federal investigators after one of its vehicles struck a pedestrian. This follows a $1.5 million civil penalty for the same incident. Autonomous technology developer May Mobility launched robotaxi operations in Ann Arbor, Michigan, without human backup drivers in the vehicles. The company previously established driverless operations in Sun City, Arizona. Market Trends and Regulatory Recent appointments announced by the incoming Trump administration include: former Wisconsin Rep. Sean Duffy to serve as the next secretary of the Department of Transportation ; Oregon Rep. Lori Chavez-DeRemer , described as a “pro-union Republican,” to lead the Labor Department ; Cantor Fitzgerald CEO Howard Lutnick to head the Commerce Department and have “additional direct responsibility” for the U.S. Trade Representative’s office; and Tesla CEO Elon Musk and entrepreneur Vivek Ramaswamy to lead a new Department of Government Efficiency tasked to “dismantle government bureaucracy, slash excess regulations, cut wasteful expenditures, and restructure federal agencies.” The National Highway Traffic Safety Administration fined Ford $165 million over claims the automaker delayed the recall of more than 600,000 vehicles with defective rearview cameras. This represents the second largest civil penalty in the agency’s history. Less than a week later, NHTSA opened separate investigations into 457,000 Ford Bronco Sport SUVs over the potential for vehicles to lose power, and roughly 113,000 Ford Expeditions due to the possibility of faulty seat belts. New passenger car registrations in Europe reached 8.9 million units for the first ten months of 2024, reflecting growth of less than 1% when compared to the same period in 2023. In the past decade, venture capitalists have invested approximately $120 billion globally into shared mobility service businesses such as ride-hailing and station-based bike systems. The Federal Communications Commission announced final rules governing cellular-vehicle-to-everything technology in the 5.9 GHz band. This is expected to promote the use of 30 megahertz of spectrum previously reserved for dedicated short-range radio communications for in-vehicle and roadside C-V2X units. Analysis by Julie Dautermann, Competitive Intelligence Analyst
Jurors end 1st day of deliberations without a verdict in the YSL gang and racketeering trialNone
How a plan to make the world's largest snowflake was humbled by nature
Explosions heard in Russia's Oryol, social media report attack on oil depot – photo, videoThe China Fund, Inc. Announces Date of Annual Meeting of Stockholders
New e-libraries to provide edu tools to Haryana cops’ families
Pasadena City Council approves $3.2 million loan for Centennial Place renovation
WASHINGTON >> Republican U.S. Senator Rand Paul voiced opposition on Sunday to the idea of using the military to carry out mass deportations of people living in the country illegally after President-elect Donald Trump signaled last week that he plans to do so. “You don’t do it with the Army because it’s illegal,” Paul said on CBS’s “Face the Nation” program. “If they send the Army into New York and you have 10,000 troops marching carrying semi-automatic weapons, I think it’s a terrible image, and I will oppose that.” A 19th-century U.S. law prohibits federal troops from being used in domestic law enforcement except when authorized by Congress. Paul, at times a maverick within his party, noted that he supports the idea of deporting people living in the United States illegally who have criminal records, but said that law enforcement authorities are better equipped than the military to carry out that role and to heed the U.S. Constitution’s Fourth Amendment prohibition on unreasonable searches and seizures. There is a “distrust of putting the Army into our streets” among Americans, Paul said. Asked if this is a red line for him and whether it would impact his Senate vote to confirm Trump’s pick of South Dakota Governor Kristi Noem to run the Department of Homeland Security, Paul said, “I will not support and will not vote to use the military in our cities.” Trump’s presidential transition team did not immediately respond to a request for comment. Trump, who built his political profile on opposition to illegal immigration, has vowed to launch the largest deportation effort in U.S. history as soon as he is sworn in on Jan. 20. He appeared to confirm in a social media post on Nov. 18 that he would declare a national emergency and use military assets for his plan to deport a record number of immigrants in the United States illegally. Paul said agents from the FBI, U.S. Immigration and Customs Enforcement and the U.S. Customs and Border Protection agency could carry out these deportations. The senator also questioned the use of the National Guard for deportations, saying it is “less clear” whether it would be legal or illegal to use these forces. The National Guard is a part of the U.S. military that answers to both the president and to state governors. Republican Rep. Byron Donalds, a member of the ultraconservative House Freedom Caucus, on Sunday described the potential use of the military in deportation campaigns as “hyperbole.” In an appearance on the Fox News program “Sunday Morning Futures,” Donalds suggested that the very threat of using the military in such a role could have a deterrent effect. “I think you’re going to see a lot of self-deportation once this process begins,” Donalds said. Other Republicans defended the idea of involving the military in the deportation effort. Sen. John Barrasso, who will be the Senate’s No. 2 Republican when his party takes control of the chamber in January, told “Fox News Sunday” that if Trump declares a national emergency “he can appropriately use the military.”Cal staves off Sacramento State for third straight win